AbbVie (ABBV) Change in Taxes (2019 - 2026)
AbbVie (ABBV) reported Change in Taxes of -$81.0 million for Q1 2026, down 121.43% year-over-year from $378.0 million in Q1 2025, and down 112.54% on a QoQ basis from $646.0 million in Q4 2025.
AbbVie (ABBV) has 8 years of Change in Taxes data on file, last reported at -$81.0 million in Q1 2026.
- Quarterly Change in Taxes fell 121.43% year-over-year to -$81.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 billion (up 61.94% YoY) and the FY2025 annual result came in at -$762.0 million, up 76.25% from the prior year.
- Change in Taxes fell to -$81.0 million in Q1 2026 per ABBV's latest filing, from $646.0 million in the prior quarter.
- Across five years, Change in Taxes topped out at $646.0 million in Q4 2025 and bottomed at -$1.8 billion in Q2 2024.
- The 5-year median for Change in Taxes is $51.0 million (2024), against an average of -$235.1 million.
- The widest annual swing landed in 2022, when Change in Taxes jumped 545.45%; it then slumped 905.88% in 2025.
- Tracing ABBV's Change in Taxes over 5 years: stood at $358.0 million in 2022, then rose by 14.8% to $411.0 million in 2023, then slumped by 538.69% to -$1.8 billion in 2024, then jumped by 135.83% to $646.0 million in 2025, then plunged by 112.54% to -$81.0 million in 2026.
- Per Business Quant, the three latest ABBV Change in Taxes figures stand at -$81.0 million (Q1 2026), $646.0 million (Q4 2025), and -$411.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | -683.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | -81.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 71.00 Mn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | -29.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 187.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -81.00 Mn |
| Mar 31, 2026 | -81.00 Mn |
| Dec 31, 2025 | 646.00 Mn |
| Dec 31, 2025 | 646.00 Mn |
| Sep 30, 2025 | -411.00 Mn |
| Sep 30, 2025 | -411.00 Mn |
| Jun 30, 2025 | -1.38 Bn |
| Jun 30, 2025 | -1.38 Bn |
| Mar 31, 2025 | 378.00 Mn |
| Mar 31, 2025 | 378.00 Mn |
| Dec 31, 2024 | -1.80 Bn |
| Dec 31, 2024 | -1.80 Bn |
| Sep 30, 2024 | 51.00 Mn |
| Sep 30, 2024 | 51.00 Mn |
| Jun 30, 2024 | -1.83 Bn |
| Jun 30, 2024 | -1.83 Bn |
| Mar 31, 2024 | 378.00 Mn |
| Mar 31, 2024 | 378.00 Mn |
| Dec 31, 2023 | 411.00 Mn |
| Dec 31, 2023 | 411.00 Mn |
| Sep 30, 2023 | 33.00 Mn |
| Sep 30, 2023 | 33.00 Mn |
| Jun 30, 2023 | -1.12 Bn |
| Jun 30, 2023 | -1.12 Bn |
| Mar 31, 2023 | 187.00 Mn |
| Mar 31, 2023 | 187.00 Mn |
| Dec 31, 2022 | 358.00 Mn |
| Dec 31, 2022 | 358.00 Mn |
| Sep 30, 2022 | 294.00 Mn |
| Sep 30, 2022 | 294.00 Mn |
| Jun 30, 2022 | -548.00 Mn |
| Jun 30, 2022 | -548.00 Mn |
| Mar 31, 2022 | 438.00 Mn |
| Mar 31, 2022 | 438.00 Mn |
| Dec 31, 2021 | -662.00 Mn |
| Dec 31, 2021 | -662.00 Mn |
| Sep 30, 2021 | -66.00 Mn |
| Sep 30, 2021 | -66.00 Mn |
| Jun 30, 2021 | -753.00 Mn |
| Jun 30, 2021 | -753.00 Mn |
| Mar 31, 2021 | 191.00 Mn |
| Mar 31, 2021 | 191.00 Mn |
| Dec 31, 2020 | -275.00 Mn |
| Dec 31, 2020 | -275.00 Mn |
| Sep 30, 2020 | -502.00 Mn |
| Sep 30, 2020 | -502.00 Mn |
| Jun 30, 2020 | 13.00 Mn |
| Jun 30, 2020 | 13.00 Mn |
| Mar 31, 2020 | 191.00 Mn |
| Mar 31, 2020 | 191.00 Mn |
| Dec 31, 2019 | -291.00 Mn |
| Dec 31, 2019 | -291.00 Mn |
| Sep 30, 2019 | 93.00 Mn |
| Sep 30, 2019 | 93.00 Mn |